There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Selective cyclooxygenase-2 (COX-2) inhibitors were developed to fill an important
medical need. The rationale for the development of selective COX-2 inhibitors will
be discussed using celecoxib as an example. A brief description of the pharmacology
and selective binding to the COX-2 enzyme will be presented. Both preclinical and
clinical data will be shown to demonstrate important clinical aspects of celecoxib.
The efficacy data will include studies of osteoarthritis, rheumatoid arthritis, and
acute pain conditions. Both gastroenterology and cardiovascular safety of celecoxib
will be discussed. Finally, potential new therapeutic areas for celecoxib will be
presented.